Search | Clinical Trials Finder

Conditions: Respiratory Tract Infection
Interventions: RSV vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 145
States / cities: Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more

Conditions: Osteoarthritis (OA) of the Knee
Interventions: Periarticular Injection, Adductor Canal Block, Bupivacaine-Meloxicam; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grosse Pointe Farms, Michigan

Conditions: Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions: Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: AZD6765 iv, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Chino, California • Lond Beach, California • San Diego, California + 30 more

Conditions: Smallpox
Interventions: Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more

Conditions: Breast Cancer
Interventions: Saline, 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rheumatoid Arthritis (RA)
Interventions: Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 44
States / cities: Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more

Conditions: Covid19
Interventions: BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB; Biological
Lead sponsor: Sohail Rao; Other
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Edinburg, Texas • Rio Grande City, Texas

Conditions: Gastroenteritis Escherichia Coli
Interventions: Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Echocardiography
Interventions: Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP); Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 1,039 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Intermittent Claudication
Interventions: Trans sodium crocetinate (TSC), 0.9% normal saline; Drug
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 40 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Birmingham, Alabama • Santa Rosa, California • Stanford, California + 4 more

Conditions: Osteoarthritis of the Hand
Interventions: AMPION™, Saline; Biological
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: COVID-19
Interventions: Interferon beta-1a, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 55
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more

Conditions: Nervous System Disorders
Interventions: Botulinum toxin type A; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 9 more

Conditions: Cytomegalovirus
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 9 Years to 25 Years
Enrollment: 873 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 44
States / cities: La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more

Conditions: Cutaneous T-cell Lymphoma
Interventions: Vitamin B12, Folic Acid, Pralatrexate; Dietary Supplement · Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 10
States / cities: Duarte, California • Redwood City, California • New Haven, Connecticut + 6 more

Conditions: Essential Tremor of the Upper Limbs
Interventions: IncobotulinumtoxinA, Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions: Sodium Nitrite, Normal Saline; Drug
Lead sponsor: Hope Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Tampa, Florida • Fort Worth, Texas

Conditions: Lassa Fever
Interventions: LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU; Biological · Other
Lead sponsor: Wilbur Chen, MD, MS; Other
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension
Interventions: Saline, QCZ484; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 64
States / cities: Andalusia, Alabama • Huntsville, Alabama • Saraland, Alabama + 59 more

Conditions: Post-operative Surgical Pain
Interventions: Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pain Management
Interventions: Bupivacaine/Epinephrine, Saline; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Interventions: Teprotumumab, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more

Conditions: Parkinson Disease
Interventions: Onabotulinumtoxin A Injection, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

Novel Extended-Release Bupivacaine Polymer for Sustained Pain Relief Following Total Knee Arthroplasty

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

MVA Post-Event: Administration Timing and Boost Study

Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

Dysport® Adult Upper Limb Spasticity Extension Study

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Botulinum Toxin A to Treat Arm Tremor

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

DMID 23-0015; Lassa Fever CVD 1000

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

Local Anesthesia for Facial Fractures

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease